サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1703442

生体吸収性冠動脈ステント市場 - 世界の産業規模、シェア、動向、機会、予測、ブランド別、エンドユーザー別、地域別、競合別、2020年～2030年

Bioresorbable Coronary Stents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Brand, By End User, By Region & Competition, 2020-2030F

出版日
ページ情報
英文 182 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

生体吸収性冠動脈ステント市場 - 世界の産業規模、シェア、動向、機会、予測、ブランド別、エンドユーザー別、地域別、競合別、2020年～2030年
出版日: 2025年04月11日
発行: TechSci Research
ページ情報: 英文 182 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

生体吸収性冠動脈ステントの世界市場は、2024年に5億5,009万米ドルとなり、予測期間中に大幅な成長を遂げ、2030年までのCAGRは10.25％を記録すると予測されています。

最近の心臓病学の進歩は、冠動脈疾患（CAD）を患う患者の予後と生活の質を著しく向上させています。こうした技術革新の中で、生体吸収性冠動脈ステントはCAD治療のパラダイムシフトを示す変革的ソリューションとして登場しました。従来の金属製ステントとは異なり、これらのステントは動脈をサポートする機能を果たした後、体内で徐々に溶解するように設計されています。

市場概要
予測期間 2026年～2030年
市場規模：2024年 5億5,009万米ドル
市場規模：2030年 9億9,008万米ドル
CAGR：2025年～2030年 10.25%
急成長セグメント 病院・クリニック
最大市場 北米

市場促進要因

心血管疾患（CVDs）の有病率の増加

市場の課題

有効性と安全性への懸念

市場動向

技術の進歩

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 生体吸収性冠動脈ステント市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • ブランド別（Magmaris、Magnitude、MeRes-100、DESolve、その他）
    • エンドユーザー別（病院・診療所、外来診療センター、その他）
    • 地域別
    • 企業別（2024年）
  • 市場マップ

第6章 北米の生体吸収性冠動脈ステント市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の生体吸収性冠動脈ステント市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋の生体吸収性冠動脈ステント市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の生体吸収性冠動脈ステント市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの生体吸収性冠動脈ステント市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 世界の生体吸収性冠動脈ステント市場：SWOT分析

第14章 競合情勢

  • BIOTRONIK SE & Co. KG
  • Meril Life Sciences Pvt. Ltd
  • Elixir Medical Corporation.
  • Reva Medical, LLC
  • Terumo Corporation
  • Lepu Medical Technology（Beijing）Co.,Ltd
  • MicroPort Scientific Corporation
  • LifeTech Scientific Corporation
  • Boston Scientific Corporation
  • Medtronic plc

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 16356

The Global Bioresorbable Coronary Stents Market was valued at USD 550.09 million in 2024 and is projected to witness substantial growth during the forecast period, registering a CAGR of 10.25% through 2030. Recent advancements in cardiology have significantly enhanced patient outcomes and quality of life for individuals suffering from coronary artery disease (CAD). Among these innovations, bioresorbable coronary stents have emerged as a transformative solution, marking a paradigm shift in CAD treatment. Unlike traditional metallic stents, these stents are designed to gradually dissolve within the body after fulfilling their function of arterial support.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 550.09 Million
Market Size 2030USD 990.08 Million
CAGR 2025-203010.25%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Market Drivers

Increasing Prevalence of Cardiovascular Diseases (CVDs)

The growing global incidence of cardiovascular diseases represents a key driver for market expansion. CVDs remain the leading cause of death globally, responsible for 17.9 million deaths in 2019-approximately 32% of global mortality. Notably, 85% of these fatalities were due to heart attacks and strokes. Furthermore, over 75% of CVD-related deaths occur in low- and middle-income countries, highlighting a critical gap in healthcare infrastructure and access to advanced cardiac care.

The rising number of patients diagnosed with coronary artery disease (CAD) has spurred demand for innovative treatment approaches like bioresorbable coronary stents. In 2022, the global prevalence of CAD was estimated at 315 million cases, with a 95% uncertainty range of 273 to 362 million. The age-standardized prevalence rate was recorded at 3,605 per 100,000 individuals, underscoring the widespread nature of the disease.

The aging global population is a significant contributing factor, as age is the most prominent non-modifiable risk factor for CAD and related cardiovascular conditions. According to the American Heart Association (AHA) 2019 update, 31% of men and 25.4% of women aged 80 and above are diagnosed with CAD. In addition, lifestyle factors such as hypertension, diabetes, obesity, and physical inactivity continue to escalate the global burden of cardiovascular risk, further supporting the shift toward bioresorbable stent adoption.

Market Challenges

Efficacy and Safety Concerns

Despite their promising potential, bioresorbable coronary stents face ongoing scrutiny regarding their clinical safety and efficacy. Some trials have raised concerns about the risk of stent thrombosis-the formation of blood clots within or near the stent-leading to potentially life-threatening complications. These concerns have prompted a comparative evaluation against conventional metallic stents, particularly in terms of long-term safety outcomes.

Market Trends

Technological Advancements

Rapid innovation in medical technology has significantly influenced the development and adoption of bioresorbable coronary stents. Continuous advancements in material science have enabled the creation of stents that maintain mechanical strength during initial healing phases while degrading safely thereafter. The use of biocompatible materials has improved both patient outcomes and procedural safety.

State-of-the-art manufacturing techniques such as 3D printing and laser cutting allow for the production of highly intricate stent designs, optimizing both radial strength and vascular conformability. Many stents are now developed with drug-eluting properties, enabling the controlled release of therapeutic agents to reduce risks of restenosis and inflammation.

Innovations in intravascular imaging technologies, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), have further enhanced procedural accuracy by providing high-resolution, real-time visualization of stent deployment. This precision supports optimal placement and expands the therapeutic potential of bioresorbable stents.

Ongoing clinical research and trials continue to refine stent designs and validate long-term outcomes, offering valuable data that guide next-generation product development and regulatory approvals.

Key Market Players

  • BIOTRONIK SE & Co. KG
  • Meril Life Sciences Pvt. Ltd
  • Elixir Medical Corporation.
  • Reva Medical, LLC
  • Terumo Corporation
  • Lepu Medical Technology (Beijing)Co.,Ltd
  • MicroPort Scientific Corporation
  • LifeTech Scientific Corporation
  • Boston Scientific Corporation
  • Medtronic plc

Report Scope:

In this report, the Global Bioresorbable Coronary Stents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bioresorbable Coronary Stents Market, By Brand:

  • Magmaris
  • Magnitude
  • MeRes-100
  • DESolve
  • Others

Bioresorbable Coronary Stents Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Bioresorbable Coronary Stents Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bioresorbable Coronary Stents Market.

Available Customizations:

Global Bioresorbable Coronary Stents market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Bioresorbable Coronary Stents Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Brand (Magmaris, Magnitude, MeRes-100, DESolve, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Bioresorbable Coronary Stents Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Brand
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bioresorbable Coronary Stents Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Brand
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Bioresorbable Coronary Stents Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Brand
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Bioresorbable Coronary Stents Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Brand
        • 6.3.3.2.2. By End User

7. Europe Bioresorbable Coronary Stents Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Brand
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bioresorbable Coronary Stents Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Brand
        • 7.3.1.2.2. By End User
    • 7.3.2. United Kingdom Bioresorbable Coronary Stents Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Brand
        • 7.3.2.2.2. By End User
    • 7.3.3. Italy Bioresorbable Coronary Stents Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Brand
        • 7.3.3.2.2. By End User
    • 7.3.4. France Bioresorbable Coronary Stents Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Brand
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Bioresorbable Coronary Stents Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Brand
        • 7.3.5.2.2. By End User

8. Asia-Pacific Bioresorbable Coronary Stents Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Brand
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Bioresorbable Coronary Stents Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Brand
        • 8.3.1.2.2. By End User
    • 8.3.2. India Bioresorbable Coronary Stents Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Brand
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Bioresorbable Coronary Stents Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Brand
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Bioresorbable Coronary Stents Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Brand
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Bioresorbable Coronary Stents Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Brand
        • 8.3.5.2.2. By End User

9. South America Bioresorbable Coronary Stents Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Brand
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Bioresorbable Coronary Stents Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Brand
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Bioresorbable Coronary Stents Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Brand
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Bioresorbable Coronary Stents Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Brand
        • 9.3.3.2.2. By End User

10. Middle East and Africa Bioresorbable Coronary Stents Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Brand
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bioresorbable Coronary Stents Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Brand
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Bioresorbable Coronary Stents Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Brand
        • 10.3.2.2.2. By End User
    • 10.3.3. UAE Bioresorbable Coronary Stents Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Brand
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Bioresorbable Coronary Stents Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. BIOTRONIK SE & Co. KG
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Meril Life Sciences Pvt. Ltd
  • 14.3. Elixir Medical Corporation.
  • 14.4. Reva Medical, LLC
  • 14.5. Terumo Corporation
  • 14.6. Lepu Medical Technology (Beijing)Co.,Ltd
  • 14.7. MicroPort Scientific Corporation
  • 14.8. LifeTech Scientific Corporation
  • 14.9. Boston Scientific Corporation
  • 14.10.Medtronic plc

15. Strategic Recommendations

16. About Us & Disclaimer